It is made available under a CC-BY-ND 4.0 International license .



Exercise intervention for the management of chemotherapy-induced peripheral neuropathy: A systematic review and network meta-analysis

- 1 Natsuki Nakagawa¹, Sena Yamamoto², Akiko Hanai^{3*}, Ayano Oiwa⁴, Harue Arao²
- 2 NN and SY contributed equally to this work.
- ³ ¹Department of Respiratory Medicine, The University of Tokyo Hospital, Department of Respiratory
- 4 Medicine, Tokyo, Japan
- ⁵ ²Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan
- ⁶ ³Advanced Data Science Project, RIKEN, Yokohama, Japan
- ⁴Department of Anesthesiology, Division of Pain Clinic, The Jikei University School of Medicine,
- 8 Tokyo, Japan
- 9
- 10 *** Correspondence:**
- 11 Akiko Hanai
- 12 akiko.hanai@riken.jp

Keywords:Cancer₁, Chemotherapy₂, Neruotoxicity₃, Quality of life₄, Systematic review₅. (Min.5-Max. 8)

15 1 Abstract

16 Although exercise is recommended for cancer survivors with chemotherapy-induced peripheral

17 neuropathy (CIPN), the effective types of exercise for preventing and treating CIPN remain unclear.

18 This systematic review and network meta-analysis (NMA) aimed to evaluate the comparative effects

19 of exercise on CIPN. We included relevant randomized controlled trials (RCTs) identified in a 2019

- 20 systematic review that evaluated the effects of exercise on CIPN and conducted an additional search
- 21 for RCTs published until 2023. We evaluated the risk of bias for each RCT; the comparative
- 22 effectiveness of exercise on patient-reported quality of life (QOL) through an NMA; and the
- 23 effectiveness of exercise on QOL scores, patient-reported CIPN symptoms, and pain through

24	additional meta-analyses. Twelve studies (exercise, n=540; control, n=527) comparing 8 exercise
25	interventions were included in the analysis. All studies were determined to have a high risk of bias.
26	The meta-analyses showed significantly improved QOL (standard mean differences [SMD] 0.45;
27	95% confidence interval [CI] = 0.12 to 0.78) and CIPN symptoms (SMD 0.46; 95% CI = 0.11 to
28	0.82). No severe adverse events were reported. Pain tended to improve with exercise (SMD 0.84;
29	95% CI = -0.11 to 1.80). An NMA suggested that the interventions of combination of balance and
30	strength training showed the significant improvement in QOL scores compared to the control.
31	Exercise interventions are safe and effective in improving QOL. For exercise categories, the
32	combination of balance and strength training would be the promising program. Patients with CIPN
33	will benefit from frequent exercise focusing on the declined symptoms.

Introduction 34 2

46

35 Approximately half of adult cancer patients receiving neurotoxic chemotherapy experience 36 chemotherapy-induced peripheral neuropathy (CIPN) (1), which frequently continues after 37 chemotherapy cessation, sometimes for years (1-3). CIPN can result in dose reduction or 38 discontinuation of cancer chemotherapy (4, 5). The rebellious and chronic nature of CIPN can lead to 39 functional and psychiatric impairment, including slower gait and a higher risk of falls compared to 40 cancer patients without CIPN (6-8). Therefore, CIPN can seriously adversely affect quality of life 41 (QOL) (2). It also causes an economic burden due to the long-term prescription of ineffective 42 analgesics for chronic CIPN (9). However, recent clinical guidelines for CIPN indicate that it is 43 difficult to establish effective management of CIPN, except that some patients may benefit from 44 duloxetine as only a partial symptomatic treatment (10, 11). 45 Previous studies have reported that physical activity and exercise improve cardiovascular

fitness, muscle strength, health-related QOL, depression, cachexia, and cancer-related fatigue (12-

This is a provisional file, not the final typeset article

47 15). Indeed, the guidelines of the American Society of Clinical Oncology (ASCO) for patients 48 receiving active cancer treatment recommend regular exercise as supportive or palliative care (16). 49 Although exercise therapy for CIPN mitigation has not been established as part of any 50 established guideline, several systematic reviews imply the potential efficacy of exercise for the 51 prevention and treatment of symptoms related to CIPN (10, 11, 13, 17-19). In these studies, the dose, 52 frequency, intensity, and duration of exercise programs varied (i.e., ranging from inactivity avoidance 53 instructions to resistance training), and the outcome (e.g., specific sensorimotor functions, activities 54 of daily living, QOL) also varied across the studies. According to the ASCO CIPN guidelines, 55 exercise therapy is not currently recommended as a preventative or treatment approach for CIPN 56 because of the low quality of the available evidence based on a systematic review of the literature 57 published between January 2013 and August 2019 (10). The guidelines state that further robust 58 research is necessary to determine the efficacy and potential risks of exercise therapy (10). In a 59 systematic review conducted by Lin et al. (17), the overall mean effect size was estimated using 60 standardized mean differences and a fixed-effect model, and significant improvement in the exercise 61 cohort compared to the control group was reported (mean difference: 0.5319; 95% confidence 62 interval: 0.2295 to 0.8344; Z = 3.45). However, the study suggested the need for further 63 investigation of different exercise protocols and intervention intensities with larger sample sizes and 64 more specific outcome measures (17). Since the publication of these systematic reviews, additional 65 clinical trials of exercise on CIPN have been published. 66 Therefore, we aimed to update the systematic reviews of randomized controlled trials (RCTs)

included in the ASCO clinical guidelines by incorporating additional recently published studies evaluating the effect of exercise on the mitigation of CIPN symptoms with an additional focus on the type of exercise program. Since CIPN symptoms and their incidence rate vary by assessment measurements (20), a consensus has been reached that clinical trials investigating CIPN should include an assessment of QOL as an indicator that best reflects the patient's life state considering

various complex symptoms (21). We conducted a meta-analysis with QOL as a primary outcome,
and specific outcomes of CIPN symptoms were also analyzed to capture changes in CIPN symptoms
associated with exercise interventions. To focus on the details and diversity of exercise intervention
programs, we conducted a network meta-analysis (NMA) to determine which exercise interventions
were most effective in improving QOL.

77 **3 Method**

78 **3.1 Study design and protocol**

79 We conducted a systematic review and meta-analysis, which followed the guidelines of the 80 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (22). 81 The review protocol was prospectively registered with the University Hospital Medical Information 82 Network Clinical Trials Registry (UMIN000045558). Ethical approval and informed consent were 83 waived considering the nature of the study. This study was conducted as a part of the Japanese 84 clinical practice guidelines on CIPN and was based on a clinical guideline previously published by 85 ASCO (10). Therefore, in the scope of guideline development, the choice was made to include all 86 randomized controlled trials comprising the ASCO systematic review as part of the current analysis 87 (23, 24).

88

89 **3.2** Literature search and data sources

In accordance with the guideline committee policy, a systematic literature search targeted studies published after September 2019 because a previous systematic literature search had been conducted in earlier clinical guidelines published by ASCO (10). A systematic literature search was performed in PubMed on April 20, 2023, to identify RCTs published between September 1, 2019, and April 20, 2023, that evaluated the effects of exercise on CIPN and included more than 5 patients in the exercise group. Interventions specialized only for the upper or lower extremities were

96 excluded. Table S3 presents the search terms used in the publication search strategy. The literature
97 search in PubMed was restricted to articles published in peer-reviewed journals and written in
98 English. In addition to the systematic literature search, we evaluated studies manually obtained
99 primarily by reviewing previously reported clinical guidelines and systematic reviews (10, 11, 13, 17,
100 25). Two authors independently screened each study for eligibility, and disagreements among
101 reviewers were resolved through discussion.

102

103 **3.3 Data extraction**

104 Two reviewers (SY and NN) independently collected the following information from each 105 included study using a predefined data extraction form: (1) general information about the study 106 (author, year of publication, country, and study design); (2) sample size; (3) patient characteristics 107 (age, sex, cancer type, anticancer drugs that could induce peripheral neuropathy, and the presence of 108 baseline CIPN); (4) exercise type, intensity, duration and frequency; (5) examined outcomes, 109 including CIPN; (6) timing of assessment of outcomes; (7) adverse effects related to the intervention; 110 and (8) enrollment rate, completion rate of the study, and adherence to the intervention. The outcome 111 measures were grouped into six categories referring to a MASCC book (25) as follows: (1) QOL 112 (primary outcome); (2) patient-reported CIPN; (3) pain; (4) clinical assessments of CIPN signs; (5) 113 balance measures; and (6) physical functional assessments. The enrollment rate was defined as the 114 proportion of screened persons who were randomly assigned. The completion rate was defined as the 115 proportion of randomly assigned persons for whom a final analysis was performed. The definition of 116 adherence to exercise intervention followed the individual studies. Discrepancies between the 117 reviewers were resolved through discussion or by a third reviewer (HA).

118

119 **3.4 Quality assessment**

It is made available under a CC-BY-ND 4.0 International license .

1	2	n
T	4	υ

121	Two reviewers (SY and NN) independently assessed the risk-of-bias using version 2 of the
122	Cochrane risk-of-bias tool for randomized trials (RoB 2) (26). All disagreements among reviewers
123	were resolved through discussion. Risk-of-bias assessments were summarized in a traffic-light plot
124	using Risk-of-bias VISualization (robvis) (27). We could not assess the risk of bias, such as
125	heterogeneity among the studies or publication bias, across the studies because many studies included
126	outcomes of different types of measurements and did not specify a primary outcome variable. A
127	funnel plot was used to check for the presence of publication bias.
128	
129	3.5 Data synthesis and meta-analyses
130	We conducted a meta-analysis on outcome data regarding QOL (primary outcome), patient-
131	reported CIPN symptoms, pain, and collected postintervention or a time point similar to
132	postintervention. We included the studies that reported the data able to calculate the mean and
133	standard deviation at each point. The standardized mean difference (SMD) was calculated due to
134	different scales used across the study outcome measures. Confidence intervals were calculated as a
135	measure of precision for the SMD estimates. If data were unavailable, we contacted the authors and
136	used all data provided by the authors after contact. If a trial was conducted with multiple parallel
137	arms including different types of exercise, we compared the outcomes by combining the arms against
138	a control. The overall mean effect sizes were estimated using random-effects models. Heterogeneity
139	was evaluated with chi-squared tests and I-square tests. We used Review Manager (RevMan, Version
140	5.4., The Cochrane Collaboration, 2020) for the meta-analysis.
1/1	

- 141
- 142 **3.6** Network meta-analysis of exercise intervention effectiveness and QOL

It is made available under a CC-BY-ND 4.0 International license .

143	A NMA was conducted to assess the comparative effectiveness of the different exercise
144	interventions in each trial, and the results represent estimates of the relative effects between any
145	given intervention pair in the NMA of QOL. The NMA was conducted using the "BUGSnet"
146	package in R and was based on Bayesian methods (28). We specified 100,000 iterations with 10,000
147	burn-ins and 10,000 adaptations based on random- and fixed-effects models and compared their
148	accuracies; we employed the model with the lowest deviance information criterion (DIC) and used
149	Bayesian Markov chain Monte Carlo modeling. The treatments were ranked according to cumulative
150	rank curve under surface (SUCRA) probabilities.
151	
152	4 Results
153	4.1 Overview of the included literature and a flow diagram
154	A total of 1640 studies that were identified for screening after applying the search terms
155	described in Table S3 were screened, and 4 studies (24, 29-31) were included in the final analysis. In
156	addition, the 2 studies (23, 32) included in the update to the ASCO guideline (10) and 6 additional
157	studies (33-38) referred to in previous systematic reviews (11, 13, 17, 25) were included. In total, 12
158	randomized controlled trials were included in the qualitative synthesis (Figure 1).
159	Details on these studies, such as patient disease diagnosis, exercise intervention, and outcome
160	measures, are provided in Table S1.Two-arm (exercise vs. control) study designs were used in 8
161	studies (23, 24, 31-36); 3-arm designs were used in 2 studies (29, 30); and 4-arm designs were used
162	in 2 studies (37, 38). The control conditions included usual care, education only, and different types
163	of nonpharmacological interventions (Reiki, meditation, cold application). All the included studies
164	aimed to assess the efficacy of exercise on CIPN. Intention-to-treat analysis was conducted in 5
165	studies (23, 24, 30, 31, 38), and per-protocol analysis was conducted in 2 studies (29, 33). In the
166	remaining 5 studies (32, 34-37), it was unclear which analysis was conducted or how missing data
167	were treated.

It is made available under a CC-BY-ND 4.0 International license .

168 4.2 Risk-of-bias assessment

169	The risk of bias was assessed by funnel plots (Figure S1), which were asymmetric and biased
170	toward positive outcomes, and by the RoB 2 tool (Figure S2). For randomization, 5 studies (24, 30,
171	32, 35, 36) were identified as having a high risk or some concerns for risk-of-bias, as they did not
172	report detailed information about randomization and/or concealment, and one study clearly described
173	that randomization was not masked (37). For deviation, all 12 studies were evaluated to have a high
174	risk of bias. For missing outcome data, 11 studies were identified as high risk or with some concerns
175	for risk-of-bias due to participants dropping out during the study (23, 24, 29-37). For measurement of
176	the outcomes, 10 out of 12 studies were evaluated to have a high risk-of-bias because outcome
177	assessors were often involved in the studies and were aware of the intervention (23, 24, 29, 30, 32-
178	34, 36-38). Finally, for selection in the reported results, 3 studies were evaluated to have a high risk-
179	of-bias because of discrepancies in the description between the methodology and reported results (24,
180	35, 38).
101	

181

182 **4.3** Study and patient characteristics

The sample sizes of the included studies ranged from 22 to 456 patients. In 6 studies (23, 24, 30, 34, 36, 37), the presence of CIPN before randomization was the eligibility criterion for the respective studies, while in 1 study (29), the absence of CIPN was the eligibility criterion. Patients with breast and gastrointestinal cancers formed the largest population. In all included studies, neurotoxic drugs were cytotoxic agents, and patients with CIPN caused by immune checkpoint inhibitors were excluded.

189

190 **4.4 Intervention details**

191 The types of exercise interventions consisted of balance training (9 studies) (23, 24, 29, 30, 192 33-36, 38), strength training (7 studies) (23, 24, 29, 30, 32, 33, 35), aerobic training (4 studies) (23, 193 31-33), and yoga (37). Balance training interventions mainly consisted of standing balanced on an 194 unstable platform under prescribed rules. Seven studies used a combination of different types of 195 exercises (23, 24, 29, 30, 32, 33, 35). In 4 studies (24, 30, 32, 36), the intervention was conducted at 196 home, largely unsupervised, with participants self-reporting their adherence. In 5 other studies (23, 197 33, 34, 37, 38), the intervention was conducted in the clinic, hospital or sports center, mostly under 198 basic supervision, with an objective assessment of adherence. In one study, participants could choose 199 the place where they would exercise (29). The length of the interventions ranged from 4 to 36 weeks 200 in 11 studies (23, 24, 30-38). In 1 study (29), the intervention continued during chemotherapy, and 201 the intervention duration was not decided beforehand. As shown in Table S1, the frequency of 202 exercise differed between the studies, ranging from 2 times a week to daily. Likewise, the length of 203 time in which participants were engaged in exercise varied in each study. Most exercise interventions 204 required less than an hour for each session. The intensity of aerobic exercise was adjusted based on 205 the participants' heart rate in all 3 studies in which the intervention included aerobic exercise (23, 32, 206 33). Moreover, the intensity was adjusted based on individual capacity (23, 29, 30, 32, 33, 35) in 6 of the 7 studies in which the intervention included strength training. For other types of intervention, the 207 208 intensity was maintained at a fixed level.

- 209
- 210 **4.5** Outcome measurement tools

The primary outcome measures of each study are described in Table S1. Patient-reported CIPN was the most frequent outcome measured (9 studies) (23, 24, 29-32, 34, 37, 38), and QOL was assessed in 8 studies (23, 24, 29, 31, 33, 35, 37, 38). Only one study evaluated the chemotherapy

It is made available under a CC-BY-ND 4.0 International license .

completion rate (29), but none of the studies assessed outcomes related to chemotherapy, includingchemotherapy dose received or survival (Table S2).

216

217	4.6 Effectiveness of exercise on patient-reported outcomes of QOL
218	Two studies (24, 33) reported a significant intervention effect on QOL. Two studies assessed
219	QOL using the European Organization for Research and Treatment of Cancer core quality of life
220	questionnaire (EORTC-QLQ-C30) (39), and one study assessed QOL using FACT-Taxane (40). The
221	other studies (23, 29, 35, 37, 38) did not detect significant differences in QOL and were assessed
222	with the EORTC-QLQ-C30 or the Functional Assessment of Cancer Therapy-General (FACT-G)
223	questionnaire (41). The synthesized data from 5 studies (23, 24, 29, 31, 37) revealed that exercise
224	significantly improved QOL (SMD, 0.45; 95% CI = 0.12 to 0.78, P = 0.008, $I^2 = 31\%$) (Figure 2A).
225	

226 4.7 Effectiveness of exercise for patient-reported CIPN symptoms

Four studies (23, 24, 30, 32) reported significant intergroup differences in patient-reported

symptoms related to CIPN, whereas four studies (29, 31, 34, 38) did not detect significant

differences. One study compared pre- and postintervention data and reported that neuropathic

symptoms significantly worsened only in the control group (37). Although three studies (23, 37, 38)

assessed patient-reported CIPN symptoms using the Functional Assessment of Cancer

232 Therapy/Gynecologic Oncology Group Neurotoxicity (FACT-GOG-NTX) questionnaire (42), the

results were inconsistent. The six studies (23, 24, 29, 31, 32, 37) included in the meta-analysis

showed a significant intervention effect on patient-reported CIPN symptoms (SMD, 0.46; 95% CI =

235 0.11 to 0.82, P = 0.01, $I^2 = 66\%$) (Figure 2B). Fear of falling was not included as a patient-reported

236 CIPN symptom in the meta-analysis because of high heterogeneity (29, 34).

237

This is a provisional file, not the final typeset article

It is made available under a CC-BY-ND 4.0 International license .

- 238 **4.8** Adverse events related to exercise
- Nine studies (23, 24, 29, 32-36, 38) reported adverse events; however, of these, only Müller
- et al. (29) reported adverse events related to the exercise programs, in which pain, fatigue and
- dizziness occurred in 21-25% of patients in the exercise group (29).
- Both studies where pain was measured using pain scales (24, 38) reported a significant
- reduction in pain in the exercise group compared to the control group. There were no significant
- 244 differences in pain scores on the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
- 245 (CIPNAT) (30) or the EORTC-QLQ-C30 (29, 33, 38). A forest plot showed no significant difference
- between the exercise groups and control groups, but a trend towards a favorable effect of exercise
- 247 was observed (SMD, 0.84; 95% CI = -0.11 to 1.80, P = 0.08, $I^2 = 91\%$) (Figure 2C).

248

249 **4.9** Clinical assessments of CIPN post-exercise intervention

250 Clinical assessments of CIPN symptoms were significantly improved by exercise in 2 out of 3 251 studies (31, 33, 38). The beneficial effects of the intervention included improvements in peripheral 252 deep sensitivity (33, 38) and Achilles tendon and patellar tendon reflexes (38). Significant 253 intervention effects on balance ability were observed in all relevant studies (23, 29, 33-36). However, 254 outcomes related to balance involved multiple measures and a wide range of signs. Mixed results 255 were observed for physical function. Four studies reported benefits to muscle strength (23, 29, 35) 256 and SPPB (31), while three studies did not show beneficial effects (33, 34, 36). 257 258 4.10 Enrollment, completion rate and adherence

Patient enrollment rates were described in 7 studies (24, 29-31, 34, 35, 37) and ranged from
25 to 100% (Table S4). Two studies (24, 35) described the reasons for the decrease in the enrollment
rate, including lack of interest, personal reasons, and unfulfilled eligibility criteria. Completion rates

were described in all studies and ranged from 64 to 100%. Six studies (23, 32, 34, 36-38) described
the reasons for the decrease in the completion rate, including death, disease progression, and
physical, psychological, and personal reasons. Adherence to the interventions was described in 8
studies (23, 24, 29, 31-33, 36, 38) and ranged from 49 to 98%. Two studies (29, 36) described the
details of the reasons for the decrease in adherence, including side effects of anticancer treatment,
time constraints and motivation.
4.11 Network meta-analysis of exercise interventions on OOL

270 A NMA was conducted to compare the effectiveness of each exercise intervention on OOL 271 and included each trial arm for which a QOL index was available (23, 24, 29, 37) (Figure 3A. 272 network graph). The fixed-effects model was selected for this data set. 273 In the SUCRA plot (Figure 3B), the curve associated with the combination treatment balance 274 and strength training had the highest probability of being ranked first among treatments, suggesting 275 that it is most likely to result in improved OOL scores. The model also generates effect estimates. 276 The difference between balance and strength training and the other treatments was larger than that of 277 the control and balance training (Figure 3C). 278 279 Discussion 5

The meta-analyses indicated that exercise was effective in improving QOL scores and patient reported CIPN symptoms. The results of the NMA on specific exercise interventions showed that the combination of balance and strength training provided the greatest benefit to QOL over the control. Severe adverse events regarding exercise were reported to be rare, and the meta-analysis showed that pain status after the exercise intervention tended to be positive in the intervention group. Considering

This is a provisional file, not the final typeset article

It is made available under a CC-BY-ND 4.0 International license .

these findings, exercise interventions that include strength training confer the greatest benefit forCIPN.

287 Our analysis with updated trials indicated that exercise positively affected QOL, consistent 288 with previous systematic reviews that showed that exercise resulted in an improvement in QOL 289 scores (SMD: 14.62, 95% CI, 6.03-3.20) (19, 43). A similar meta-analysis of studies on the severity 290 of CIPN and peripheral deep sensitivity showed positive results, as in our research on QOL(44). 291 These exercise interventions differed among the 12 studies included in this systematic review. 292 Concerning intervention programs, a daily home-based program combining balance and strength 293 training was suggested to have the greatest improvement in QOL compared with that of the control 294 group, but the differences were not statistically significant in the NMA. While most of the other 295 studies included in this analysis used an exercise frequency of 2-3 times per week, the trial that used 296 the Strength + Balance exercise intervention had a daily home-based intervention, suggesting that a 297 high frequency of specialized exercise was implemented. These results are similar to those of a 298 clinical trial that compared different doses and modes of exercise for breast cancer patients who 299 underwent chemotherapy and showed that compared with standard volumes, a higher volume of 300 aerobic or combined exercise may better manage declines in physical functioning and worsening 301 symptoms (45). Although exercise relieves general chronic pain, it causes acute muscle pain (46); 302 however, the results of this study suggest that strength exercise does not cause pain in patients with 303 CIPN. In cancer patients, intrapersonal factors (functional status or pain, interest in exercise, and 304 beliefs about the importance of exercise) are related to low physical activity (47). However, it is 305 recommended for general cancer survivors to avoid physical inactivity and perform at least 150-300 306 minutes of moderate-intensity exercise or 75 minutes of high-intensity exercise, or an equivalent 307 combination, per week, with at least two days of resistance training (muscle strengthening exercise) 308 (15, 48). Implementing these common exercise recommendations for cancer survivors is expected to 309 improve pain and remove the barriers to exercise. The results of this NMA suggest that a program

It is made available under a CC-BY-ND 4.0 International license .

that adds balance training to these exercise recommendations may help improve the QOL of CIPNpatients.

312 There are two limitations of this research. First, the included studies are predominantly small 313 exploratory studies with limited information, and it is difficult to exclude the possibility that study 314 biases may have led to positive results. It is recommended that the effect-size metrics selected for the 315 meta-analysis be comparable and reliable, but none of them are perfect in this report. The funnel plot 316 results were asymmetric and biased towards positive outcomes, which indicates selection bias. There 317 are several reasons why bias may have been observed, including protocol deviations due to 318 individual differences in exercise performance, self-reported outcome measures, nonblinded 319 interventions, and the possibility of survival bias among patients with high adherence to the 320 described study protocols. In addition, CIPN symptoms are influenced by the type and schedule of 321 chemotherapy, but no study has established or described those factors in detail. Therefore, 322 differences in the target population may have influenced the results. The consideration of these 323 sources of potential bias is important when interpreting the results of these exercise interventions. 324 Furthermore, isolating an actual intervention effect from a placebo effect is difficult to achieve, as 325 participation in a study itself may lead to improvements in motivation and physical and mental 326 function. Altogether, this highlights the clinical importance of conducting a meta-analysis and NMA 327 to consider the totality of evidence that supports the claim for exercise in the management of CIPN. 328 Second, many trials did not specify whether the tested intervention was intended to prevent or 329 treat CIPN. Since symptoms of CIPN can occur in either limb, interventions should ensure that 330 assessments are made at the site of CIPN onset. However, it is difficult to predict the CIPN site and 331 complete a functional assessment and intervention by the site in the research framework, especially in 332 prevention research. For future research, it is important to design exercise interventions with multiple 333 effects and evaluation methods, such as large-scale clinical trials with subgroup analysis, in advance.

This is a provisional file, not the final typeset article

It is made available under a CC-BY-ND 4.0 International license .

334 Based on the results of this study, it is expected that not only would a reduction in CIPN 335 symptoms improve QOL but also that an improvement in basic physical functions, such as 336 underlying physical fitness, has a synergistic effect of enabling a more active lifestyle and improving 337 QOL. The present NMA could not show the significant effects but suggested that a combination of 338 balance and strength training, which require the supervision of exercise specialists and the creation of 339 an appropriate environment. The implementation of active lifestyles is recommended (15), and they 340 can be easily introduced into the daily lives of cancer patients. However, our NMA results suggest 341 that high-frequency combined strength and balance exercise interventions are preferable for reducing 342 CIPN, which requires more specialized guidance than general lifestyle physical activities.

343

344 6 CONCLUSION

345 Our results indicate that the exercise interventions implemented in the RCTs are effective in 346 improving QOL and CIPN symptoms. While increasing physical activity would enhance general 347 QOL and aerobic exercise is observed to be an effective approach, the combination of balance and 348 strength training provides the great benefits in CIPN patients. Our meta-analysis results strengthen 349 the evidence that exercise benefits the QOL of CIPN patients. Furthermore, daily exercise with a 350 combination of balance and strength training would promise for improving QOL. 351 Further research on how to implement a system incorporating more specialized and intense 352 exercise in this patient population is needed to achieve exercise implementation based on an

- assessment of balancing ability and efficient strength training on a continuous basis.
- **354 7 Conflict of Interest**

355 The authors declare they have no financial interests.

356 8 Author Contributions

357	All authors contributed to the idea for the article and the search strategy planning. NN, SY, AO and
358	HA conducted screening of the articles. NN and SY performed data extraction and quality
359	assessment. AO and HA contributed to review of the data. NN, SY, and AH drafted the manuscript.
360	AO and HA critically revised the drafted manuscript. All authors have reviewed and approved the
361	submitted version of the manuscript.
362	9 Funding
363	This work was supported by a JSPS Grant-in-Aid for Research Activity Start-up (19K21293) for
364	A.H.
365	10 Acknowledgments
366	We would like to thank the authors of the original papers who provided us with information for this
367	study.
368	11 References
369	1. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence,
370	prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and
371	meta-analysis. Pain (2014) 155:2461-70.
372	2. Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G. Chemotherapy-induced
373	peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. The
374	Journal of community and supportive oncology (2014) 12:401-6.
375	3. Kneis S, Wehrle A, Müller J, Maurer C, Ihorst G, Gollhofer A, et al. It's never too late -
376	balance and endurance training improves functional performance, quality of life, and alleviates
377	neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral
378	neuropathy: results of a randomized controlled trial. BMC Cancer (2019) 19:414.
379	4. DiBonaventura MD, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and

This is a provisional file, not the final typeset article

It is made available under a CC-BY-ND 4.0 International license .

380 treatment adherence among women diagnosed with metastatic breast cancer. American health & drug

381 benefits (2014) 7:386–96.

3825.Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. Journal of

the National Comprehensive Cancer Network : JNCCN (2009) 7:99–108.

- 384 6. Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, et al. Falls,
- functioning, and disability among women with persistent symptoms of chemotherapy-induced
- 386 peripheral neuropathy. Journal of clinical oncology : official journal of the American Society of
- 387 Clinical Oncology (2017) 35:2604–12.
- 388 7. Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, et al.

389 Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based

cohort. Journal of neurology, neurosurgery, and psychiatry (2018) 89:636–41.

- 391 8. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of
- 392 chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA neurology393 (2016) 73:860–6.
- Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced
 peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast
 cancer research and treatment (2016) 159:327–33.
- 397 10. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and

398 management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO

- 399 guideline update. Journal of clinical oncology : official journal of the American Society of Clinical
- 400 Oncology (2020) 38:3325–48.
- 401 11. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic
- 402 anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical
- 403 Practice Guidelines for diagnosis, prevention, treatment and follow-up. Annals of oncology : official
- 404 journal of the European Society for Medical Oncology (2020) 31:1306–19.

- 405 12. Hong Y, Wu C, Wu B. Effects of Resistance Exercise on Symptoms, Physical Function, and
- 406 Quality of Life in Gastrointestinal Cancer Patients Undergoing Chemotherapy. Integr Cancer Ther
- 407 (2020) 19:1534735420954912. doi: 10.1007/s11764-019-00772-y
- 408 13. Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, Di Blasio A, et al. Effects of exercise
- 409 on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a
- 410 systematic review. Critical reviews in oncology/hematology (2018) 121:90–100.
- 411 14. Fuller JT, Hartland MC, Maloney LT, Davison K. Therapeutic effects of aerobic and
- 412 resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br J
- 413 Sports Med (2018) 52:1311. doi: 10.1136/bjsports-2017-098285
- 414 15. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al.
- 415 Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary
- 416 roundtable. Medicine and science in sports and exercise (2019) 51:2375–90.
- 417 16. Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, et al.
- 418 Exercise, diet, and weight management during cancer treatment: ASCO guideline. Journal of clinical
- 419 oncology : official journal of the American Society of Clinical Oncology (2022) 40:2491–507.
- 420 17. Lin WL, Wang RH, Chou FH, Feng IJ, Fang CJ, Wang HH. The effects of exercise on
- 421 chemotherapy-induced peripheral neuropathy symptoms in cancer patients: a systematic review and
- 422 meta-analysis. Supportive care in cancer : official journal of the Multinational Association of
- 423 Supportive Care in Cancer (2021) 29:5303–11.
- 424 18. Kanzawa-Lee GA, Larson JL, Resnicow K, Smith EML. Exercise effects on chemotherapy-
- 425 induced peripheral neuropathy: a comprehensive integrative review. Cancer nursing (2020) 43:E172–
- 426 85. doi: 10.1097/NCC.000000000000801
- 427 19. Lopez-Garzon M, Cantarero-Villanueva I, Postigo-Martin P, González-Santos Á, Lozano-
- 428 Lozano M, Galiano-Castillo N. Can physical exercise prevent chemotherapy-induced peripheral
- 429 neuropathy in patients with cancer? A systematic review and meta-analysis. Archives of physical

This is a provisional file, not the final typeset article

430 medicine and rehabilitation (2022) 103:2197–208.

431 20. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are we mis-estimating

- 432 chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a
- 433 prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
- 434 BMC Cancer (2019) 19:132. doi: 10.1186/s12885-019-5302-4
- 435 21. Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, et al. The national
- 436 cancer institute clinical trials planning meeting for prevention and treatment of chemotherapy-
- 437 induced peripheral neuropathy. Journal of the National Cancer Institute (2019) 111:531–7.
- 438 22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- 439 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical
- 440 research ed) (2021) 372:n71. doi: 10.1136/bmj.n71
- 441 23. Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week,
- 442 multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and
- 443 improves balance and strength in metastasized colorectal cancer patients: a randomized controlled
- 444 trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care
- 445 in Cancer (2018) 26:615–24.
- 24. Dhawan S, Andrews R, Kumar L, Wadhwa S, Shukla G. A randomized controlled trial to
 assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced
 peripheral neuropathic pain and quality of life among cancer patients. Cancer nursing (2020) 43:269–
 80.
- 450 25. Kleckner IR, Park SB, Streckmann F, Wiskemann J, Hardy S, Mohile N. Systematic review
 451 of exercise for prevention and management of chemotherapy-induced peripheral neuropathy. In:
- 452 Lustberg M, Loprinzi C, editors. Diagnosis, Management and Emerging Strategies for
- 453 Chemotherapy-Induced Neuropathy: A MASCC Book. Cham: Springer International Publishing;
- 454 2021. p. 183–241.

- 455 26. Higgins J, Savović J, Page M, Elbers RG, Sterne JA. Assessing risk of bias in a randomized
- 456 trial. In: Higgins J, Thomas J, Chandler J, M C, Li T, Page M, et al., editors. Cochrane Handbook for
- 457 Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019. p. 736.
- 458 27. McGuinness LA, Higgins JPT. Risk-of-bias visualization (robvis): an R package and shiny
- 459 web app for visualizing risk-of-bias assessments. Research synthesis methods (2021) 12:55–61.
- 460 28. Béliveau A, Boyne DJ, Slater J, Brenner D, Arora P. BUGSnet: an R package to facilitate the
- 461 conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol (2019) 19:196.
- 462 doi: 10.1186/s12874-019-0829-2
- 463 29. Müller J, Weiler M, Schneeweiss A, Haag GM, Steindorf K, Wick W, et al. Preventive effect
- 464 of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a
- 465 randomised-controlled trial. British journal of cancer (2021) 125:955–65.
- 466 30. Şimşek NY, Demir A. Cold application and exercise on development of peripheral
- 467 neuropathy during taxane chemotherapy in breast cancer patients: a randomized controlled trial.
- 468 Asia-Pacific journal of oncology nursing (2021) 8:255–66.
- 469 31. Saraboon C, Siriphorn A. Effects of foam pad balance exercises on cancer patients
- 470 undergoing chemotherapy: a randomized control trial. Journal of bodywork and movement therapies
- 471 (2021) 28:164–71.
- 472 32. Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of
- 473 exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter,
- 474 randomized controlled trial. Supportive care in cancer : official journal of the Multinational
- 475 Association of Supportive Care in Cancer (2018) 26:1019–28.
- 476 33. Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program
- 477 improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy.
- 478 Annals of oncology : official journal of the European Society for Medical Oncology (2014) 25:493–9.
- 479 34. Schwenk M, Grewal GS, Holloway D, Muchna A, Garland L, Najafi B. Interactive sensor-

This is a provisional file, not the final typeset article

480 based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a

481 randomized controlled trial. Gerontology (2016) 62:553–63.

482 35. Vollmers PL, Mundhenke C, Maass N, Bauerschlag D, Kratzenstein S, Röcken C, et al.

483 Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast

484 cancer patients undergoing neurotoxic chemotherapy. Journal of cancer research and clinical

485 oncology (2018) 144:1785–92.

486 36. Stuecher K, Bolling C, Vogt L, Niederer D, Schmidt K, Dignaß A, et al. Exercise improves

487 functional capacity and lean body mass in patients with gastrointestinal cancer during chemotherapy:

488 a single-blind RCT. Supportive care in cancer : official journal of the Multinational Association of

489 Supportive Care in Cancer (2019) 27:2159–69.

490 37. Clark PG, Cortese-Jimenez G, Cohen E. Effects of reiki, yoga, or meditation on the physical

491 and psychological symptoms of chemotherapy-induced peripheral neuropathy: a randomized pilot

492 study. J Evid-Based Complement Altern Med (2012) 17:161–71.

493 38. Streckmann F, Lehmann HC, Balke M, Schenk A, Oberste M, Heller A, et al. Sensorimotor

494 training and whole-body vibration training have the potential to reduce motor and sensory symptoms

495 of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial. Supportive care

496 in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)

497 27:2471-8.

498 39. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European

499 Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in

500 international clinical trials in oncology. Journal of the National Cancer Institute (1993) 85:365–76.

501 40. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of

502 taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane).

503 Cancer (2003) 98:822–31.

504 41. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional

505	Assessi	ment of Cancer Therapy scale: development and validation of the general measure. Journal of
506	clinical	oncology : official journal of the American Society of Clinical Oncology (1993) 11:570-9.
507	42.	Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al.
508	Psycho	metric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology
509	Group-	Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.
510	Internat	tional journal of gynecological cancer : official journal of the International Gynecological
511	Cancer	Society (2003) 13:741–8.
512	43.	Tanay MAL, Armes J, Moss-Morris R, Rafferty AM, Robert G. A systematic review of
513	behavio	oural and exercise interventions for the prevention and management of chemotherapy-induced
514	periphe	eral neuropathy symptoms. Journal of cancer survivorship : research and practice (2023)
515	17:254-	-77.
516	44.	Nuñez de Arenas-Arroyo S, Cavero-Redondo I, Torres-Costoso A, Reina-Gutiérrez S,
517	Lorenze	o-García P, Martínez-Vizcaíno V. Effects of exercise interventions to reduce chemotherapy-
518	induced	d peripheral neuropathy severity: A meta-analysis. Scand J Med Sci Sports (2023) 33:1040-53.
519	45.	Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, et al.
520	Effects	of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial.
521	Journal	of the National Cancer Institute (2013) 105:1821–32.
522	46.	Dannecker EA, Koltyn KF. Pain during and within hours after exercise in healthy adults.
523	Sports	medicine (Auckland, NZ) (2014) 44:921–42.
524	47.	Chou YJ, Lai YH, Lin BR, Liang JT, Shun SC. Factors influencing amount of weekly
525	exercise	e time in colorectal cancer survivors. Cancer nursing (2017) 40:201-8.
526	48.	Lindell M, Grimby-Ekman A. Stress, non-restorative sleep, and physical inactivity as risk
527	factors	for chronic pain in young adults: A cohort study. PLoS One (2022) 17:e0262601. doi:
528	10.137	1/journal.pone.0262601

This is a provisional file, not the final typeset article

It is made available under a CC-BY-ND 4.0 International license .

529

530 12 Figure and Table Legends

- 531 **Figure 1.** PRISMA flow diagram
- 532 Figure 2. Forest plots of the effects of exercise on patient-reported outcomes. (A) Quality of life
- 533 (QOL), (B) Patient-reported CIPN symptoms, (C) Pain
- **Figure 3.** Network meta-analysis(A) network graph, (B) SUCRA plot, (C) League Table Heatmap.
- 535 The values in each cell show the relative treatment effect and 95% credible intervals of the treatment
- on the top, compared to the treatment on the left. The double asterisks: statistical significance.

537 Supplementary materials

- 538 **Table S1.** Overview of included studies
- 539 Table S2. Summary of main results regarding the effect of exercise on outcomes
- 540 **Table S3.** The detail of search strategy in this study
- 541 **Table S4.** Enrollment, completion rate and adherence
- 542 Figure S1. Funnel plot of comparison: Exercise versus control, outcome. (A) Quality of life (QOL),
- 543 (B) Patient-reported CIPN symptoms, (C) Pain
- 544 **Figure S2.** Risk of bias assessment

545 1 Data Availability Statement

- 546 The data that support the findings of this study are available from the corresponding author upon
- 547 reasonable request.

It is made available under a CC-BY-ND 4.0 International license .

PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases and registers only




Figure 1. PRISMA flow diagram

Figure 2

A. QOL

Exercise			0	Control			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Clark et al. [37]	116.8	11.46	7	110.17	20.25	7	8.6%	0.38 [-0.68, 1.44]	
Dhawan et al. [24]	61.7	20.5	22	43.1	18.9	23	20.1%	0.93 [0.31, 1.55]	_
Müller et al. [29]	59.8311	20.7139	103	56.4	22.7	56	40.1%	0.16 [-0.17, 0.49]	- +
Saraboon and Siriphorn [31]	155.27	7.39	15	148.87	8.98	15	15.3%	0.76 [0.01, 1.50]	
Zimmer et al. [23]	82.637	15.432	17	77.897	12.032	13	15.9%	0.33 [-0.40, 1.06]	
Total (95% CI)			164			114	100.0%	0.45 [0.12, 0.78]	-
Heterogeneity: Tau ² = 0.04; Chi ² = 5.78, df = 4 (P = 0.22); I ² = 31%								-2	
Test for overall effect: Z = 2.65 (P = 0.008)								-2	Favours [control] Favours [exercise]


B. Patient-reported CIPN symptoms

	Ex	ercise	Control			Std. Mean Difference			Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI	
Clark et al. [37]	32.43	3.55	7	27.86	9.82	7	8.0%	0.58 [-0.50, 1.66]			
Dhawan et al. [24]	-83.1	46.5	22	-140.8	42.9	23	15.1%	1.27 [0.62, 1.91]		_	
Kleckner et al. [32]	-1.1	1.9814	170	-1.64	2.344	185	27.0%	0.25 [0.04, 0.46]			
Müller et al. [29]	-14.8524	16.3692	103	-14.3	15.3	56	23.9%	-0.03 [-0.36, 0.29]		_ _	
Saraboon and Siriphorn [31]	-0.07	0.26	15	-0.33	0.62	15	13.2%	0.53 [-0.20, 1.26]			
Zimmer et al. [23]	35.2353	6.6	17	28.974	9.92	13	12.8%	0.74 [-0.01, 1.49]			
Total (95% CI)			334			299	100.0%	0.46 [0.11, 0.82]		-	
Heterogeneity: Tau ² = 0.11; Chi ² = 14.90, df = 5 (P = 0.01); I ² = 66%								-2			
Test for overall effect: Z = 2.54 (P = 0.01)									-2	-1 U 1 Favours [control] Favours [exercise]	

C. Pain

Excercise			C	ontrol			Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
Dhawan et al. [24]	-10.7	5.6	22	-15.8	4.1	23	31.9%	1.02 [0.40, 1.65]	_	
Müller et al. (29)	-22.8854	26.2218	103	-24.4	29.3	56	35.5%	0.06 [-0.27, 0.38]		
Şimşek and Demir (30)	-3.4	2.2	30	-6.3	1.5	30	32.6%	1.52 [0.94, 2.10]		
Total (95% CI)			155			109	100.0%	0.84 [-0.11, 1.80]		
Heterogeneity: Tau ² = 0.64; Chi ² = 21.80, df = 2 (P < 0.0001); l ² = 91%								_		
Test for overall effect: Z = 1.73 (P = 0.08)									Favours [control] Favours [exercise]	

Figure 3



(С	Treatment												
		Control	Aerobic+Balance+Strength	Balance	Balance+Strength	Strength	Yoga							
	Control		4.69 (-5.14, 14.56)	1.79 (-6.64, 10.22)	**18.62** (7.07, 30.19)	4.79 (-3.17, 12.72)	6.76 (-10.45, 23.99)							
Aer	robic+Balance+Strength	-4.69 (-14.56, 5.14)		-2.90 (-15.82, 10.01)	13.94 (-1.29, 29.02)	0.10 (-12.55, 12.67)	2.09 (-17.81, 21.84)							
Comparator	Balance	-1.79 (-10.22, 6.64)	2.90 (-10.01, 15.82)		**16.83** (2.56, 31.10)	3.00 (-4.95, 10.94)	4.95 (-14.17, 24.18)							
Comp	Balance+Strength	**-18.62** (-30.19, -7.07)	-13.94 (-29.02, 1.29)	**-16.83** (-31.10, -2.56)		-13.82 (-27.83, 0.19)	-11.87 (-32.51, 8.78)							
	Strength	-4.79 (-12.72, 3.17)	-0.10 (-12.67, 12.55)	-3.00 (-10.94, 4.95)	13.82 (-0.19, 27.83)		1.96 (-16.92, 21.00)							
	Yoga	-6.76 (-23.99, 10.45)	-2.09 (-21.84, 17.81)	-4.95 (-24.18, 14.17)	11.87 (-8.78, 32.51)	-1.96 (-21.00, 16.92)								